MD Anderson Ovarian SPORE publications – 2010
1.
Agarwal R, Carey M, Hennessy B, Mills GB. PI3K pathway-directed therapeutic strategies in
cancer. Curr Opin Investig Drugs 11(6):615-28, 2010. PMID: 20496256.
2.
Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le
XF, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D,
Glover DM, Sood AK, Bast RC Jr. SIK2 is a centrosome kinase required for bipolar mitotic spindle
formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18(2):109-21,
2010. PMID: 20708153; PMCID: PMC3954541.
3.
An J, Wei Q, Liu Z, Lu KH, Cheng X, Mills GB, Wang LE. Messenger RNA expression and
methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control
analysis. Int J Mol Epidemiol Genet 1(1):1-10, 2010. PMID: 20689651; PMCID: PMC2916180.
4.
Bast RC Jr. Biomarkers for ovarian cancer: new technologies and targets to address persistently
unmet needs. Cancer Biomark 8(4-5):161-6, 2010. PMID: 22045350.
5.
Bast RC Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate
biomarker for a difficult disease. Cancer 116(12):2850-3, 2010. PMID: 20564390; PMCID:
PMC2988470.
6.
Bast RC Jr, Markman M. Chemotherapy: A new standard combination for recurrent ovarian
cancer? Nat Rev Clin Oncol 7(10):559-60, 2010. PMID: 20877420; PMCID: PMC2956193.
7.
Bast RC Jr, Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin
Oncol 28(22):3545-8, 2010. PMID: 20547987.
8.
Brown J, Smith JA, Ramondetta LM, Sood AK, Ramirez PT, Coleman RL, Levenback CF, Munsell MF,
Jung M, Wolf JK. Combination of gemcitabine and cisplatin is highly active in women with
endometrial carcinoma: results of a prospective phase 2 trial. Cancer 116(21):4973-9, 2010.
PMID: 20665499.
9.
Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR,
Miller D, Huntsman D, Mills GB, Hennessy BT. Functional proteomic analysis of advanced serous
ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates
response to primary chemotherapy. Clin Cancer Res 16(10):2852-60, 2010. PMID: 20460476;
PMCID: PMC2877659.
10.
Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK,
Ellenson LH, Hermeking H, Nikitin AY. Frequent downregulation of miR-34 family in human ovarian
cancers. Clin Cancer Res 16(4):1119-28, 2010. PMID: 20145172; PMCID: PMC2822884.
11.
Creighton CJ, Benham AL, Zhu H, Khan MF, Reid JG, Nagaraja AK, Fountain MD, Dziadek O, Han D,
Ma L, Kim J, Hawkins SM, Anderson ML, Matzuk MM, Gunaratne PH. Discovery of novel microRNAs
in female reproductive tract using next generation sequencing. PLoS One 5(3):e9637, 2010.
PMID: 20224791; PMCID: PMC2835764.
12.
Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M, Marini FC. Reduction
of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating
viruses transported in mesenchymal stem cells. Cancer Gene Ther 17(4):289-97, 2010. PMID:
19876078.
13.
Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC Jr, Zhang Z, Nicoletto MO. Combined use of
biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol 31(3):209-15, 2010.
PMID: 20393825.
14.
Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. Unmasking the complexities of
mucinous ovarian carcinoma. Gynecol Oncol 117(3):491-6, 2010. PMID: 20332054.
15.
Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC. Upregulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol
Oncol 119(1):114-20, 2010. PMID: 20619446; PMCID: PMC3000175.
16.
Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a
systems biology approach. J Clin Oncol 28(16):2777-83, 2010. PMID: 20406928; PMCID:
PMC2881854.
17.
Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C,
Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Targeted gene silencing using RGDlabeled chitosan nanoparticles. Clin Cancer Res 16(15):3910-22, 2010. PMID: 20538762; PMCID:
PMC2912984.
18.
Hawkins SM, Matzuk MM. Oocyte-somatic cell communication and microRNA function in the
ovary. Ann Endocrinol (Paris) 71(3):144-8, 2010. PMID: 20362967; PMCID: PMC2917249.
19.
Hennessey VG, Rosner GL, Bast RC Jr, Chen MY. A Bayesian approach to dose-response
assessment and synergy and its application to in vitro dose-response studies. Biometrics
66(4):1275-83, 2010. PMID: 20337630; PMCID: PMC3773943.
20.
Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, 2nd, Abkevich V, Potter J, Pruss
D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS,
Lu KH, Mills GB. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients
that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol
28(22):3570-6, 2010. PMID: 20606085; PMCID: PMC2917312.
21.
Huang J, Hu W, Sood AK. Prognostic biomarkers in ovarian cancer. Cancer Biomark 8(4-5):231-51,
2010. PMID: 22045356.
22.
Huang S, Chang IS, Lin W, Ye W, Luo RZ, Lu Z, Lu Y, Zhang K, Liao WS, Tao T, Bast RC Jr, Chen X,
Yu Y. ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks
nuclear import of cargo proteins. Biosci Rep 30(3):159-68, 2010. PMID: 19435463; PMCID:
PMC2974631.
23.
Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson
DM, Coleman RL, Bischoff FZ, Sood AK. Plasma cell-free DNA in ovarian cancer: an independent
prognostic biomarker. Cancer 116(8):1918-25, 2010. PMID: 20166213; PMCID: PMC2854845.
24.
Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC
Jr. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in
platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol 3:9,
2010. PMID: 20222977; PMCID: PMC2851575.
25.
Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, Shi Y, Abbruzzese J, Konopleva M,
Andreeff M, Marini FC. Mesenchymal stromal cells alone or expressing interferon-beta suppress
pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy
12(5):615-25, 2010. PMID: 20230221.
26.
Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, Du Y, Xie X, Wei Y, Xia W, Weihua Z, Yang JY,
Yen CJ, Huang TH, Tan M, Xing G, Zhao Y, Lin CH, Tsai SF, Fidler IJ, Hung MC. ARD1 stabilization
of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci Signal 3(108):ra9,
2010. PMID: 20145209; PMCID: PMC2874891.
27.
Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB,
Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde
dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9(12):3186-99, 2010. PMID:
20889728; PMCID: PMC3005138.
28.
Le XF, Mao W, Lu Z, Carter BZ, Bast RC Jr. Dasatinib induces autophagic cell death in human
ovarian cancer. Cancer 116(21):4980-90, 2010. PMID: 20629079; PMCID: PMC2975555.
29.
Le XF, Merchant O, Bast RC, Calin GA. The Roles of MicroRNAs in the Cancer InvasionMetastasis Cascade. Cancer Microenviron 3(1):137-47, 2010. PMID: 21209780; PMCID:
PMC2990485.
30.
Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J. Stanniocalcin 1
and ovarian tumorigenesis. J Natl Cancer Inst 102(11):812-27, 2010. PMID: 20484106; PMCID:
PMC2879417.
31.
Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL,
Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K,
Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO,
Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ,
Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell
18(2):185-97, 2010. PMID: 20708159; PMCID: PMC2923653.
32.
Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS,
Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting
pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 9(3):17682, 2010. PMID: 20009575; PMCID: PMC3155813.
33.
Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: biobehavioral
signaling pathways and interventions. J Clin Oncol 28(26):4094-9, 2010. PMID: 20644093; PMCID:
PMC2940426.
34.
Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK. Clinical relevance of extent of extreme drug
resistance in epithelial ovarian carcinoma. Gynecol Oncol 116(1):61-5, 2010. PMID: 19840886.
35.
Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma.
Expert Opin Investig Drugs 19(11):1339-54, 2010. PMID: 20815774; PMCID: PMC2962713.
36.
Merritt WM, Bar-Eli M, Sood AK. The dicey role of Dicer: implications for RNAi therapy. Cancer
Res 70(7):2571-4, 2010. PMID: 20179193; PMCID: PMC3170915.
37.
Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth
WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK. Bridging the gap between
cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol
Cancer Ther 9(4):985-95, 2010. PMID: 20371710; PMCID: PMC2852465.
38.
Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC,
Skates SJ. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the
prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol
203(3):228.e1-6, 2010. PMID: 20471625; PMCID: PMC3594101.
39.
Moore RG, MacLaughlan S, Bast RC Jr. Current state of biomarker development for clinical
application in epithelial ovarian cancer. Gynecol Oncol 116(2):240-5, 2010. PMID: 19879639;
PMCID: PMC3134885.
40.
Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Future Oncol
6(12):1863-81, 2010. PMID: 21142861; PMCID: PMC3037818.
41.
Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT,
Hawkins SM, Anderson ML, Matzuk MM. A link between mir-100 and FRAP1/mTOR in clear cell
ovarian cancer. Mol Endocrinol 24(2):447-63, 2010. PMID: 20081105; PMCID: PMC2817607.
42.
Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A. Serum
biomarker panels for the discrimination of benign from malignant cases in patients with an
adnexal mass. Gynecol Oncol 117(3):440-5, 2010. PMID: 20334903; PMCID: PMC2873171.
43.
Ozpolat B, Sood AK, Lopez-Berestein G. Nanomedicine based approaches for the delivery of
siRNA in cancer. J Intern Med 267(1):44-53, 2010. PMID: 20059643.
44.
Prathapam T, Aleshin A, Guan Y, Gray JW, Martin GS. p27Kip1 mediates addiction of ovarian
cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs. J Biol Chem
285(42):32529-38, 2010. PMID: 20647308; PMCID: PMC2952255.
45.
Saad AF, Hu W, Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer. Horm
Cancer 1(6):277-90, 2010. PMID: 21761359; PMCID: PMC3199131.
46.
Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM,
Ramirez PT. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary.
Obstet Gynecol 116(2 Pt 1):269-73, 2010. PMID: 20664385.
47.
Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW,
Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW,
Sood AK. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and
metastasis. J Biol Chem 285(46):35462-70, 2010. PMID: 20826776; PMCID: PMC2975170.
48.
Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers
MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin
YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf
SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from
anoikis. J Clin Invest 120(5):1515-23, 2010. PMID: 20389021; PMCID: PMC2860925.
49.
Sood AK, Coleman RL. Targeted therapy in gynecologic oncology: biology, strategy, and
assessment. Gynecol Oncol 116(2):155-6, 2010. PMID: 20109724.
50.
Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith
M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y,
Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from
parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 9(8):2377-88, 2010.
PMID: 20682653; PMCID: PMC2933364.
51.
Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin
Biol Ther 10(3):431-7, 2010. PMID: 20092424.
52.
Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic
therapies in ovarian cancer. Lancet Oncol 11(5):465-75, 2010. PMID: 20226736; PMCID:
PMC3199129.
53.
Su JL, Chen PB, Chen YH, Chen SC, Chang YW, Jan YH, Cheng X, Hsiao M, Hung MC.
Downregulation of microRNA miR-520h by E1A contributes to anticancer activity. Cancer Res
70(12):5096-108, 2010. PMID: 20501832; PMCID: PMC2891368.
54.
Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM,
Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM,
Lopez-Berestein G, Sood AK, Ferrari M. Sustained small interfering RNA delivery by mesoporous
silicon particles. Cancer Res 70(9):3687-96, 2010. PMID: 20430760; PMCID: PMC3202607.
55.
Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A,
Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A,
Peng Z, Sood AK, Lopez-Berestein G. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in
ovarian cancer. Clin Cancer Res 16(1):184-94, 2010. PMID: 20028751; PMCID: PMC3716580.
56.
Weinrib AZ, Sephton SE, Degeest K, Penedo F, Bender D, Zimmerman B, Kirschbaum C, Sood AK,
Lubaroff DM, Lutgendorf SK. Diurnal cortisol dysregulation, functional disability, and depression
in women with ovarian cancer. Cancer 116(18):4410-9, 2010. PMID: 20564155; PMCID:
PMC3118555.
57.
Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM.
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol
177(4):1611-7, 2010. PMID: 20802181; PMCID: PMC2947258.
58.
Yamaguchi H, Chen CT, Chou CK, Pal A, Bornmann W, Hortobagyi GN, Hung MC. Adenovirus 5 E1A
enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim
upregulation. Oncogene 29(41):5619-29, 2010. PMID: 20676141; PMCID: PMC2955174.
59.
Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S,
Multani AS, Mercado-Uribe I, Liu J. Aurora kinase A promotes ovarian tumorigenesis through
dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res 16(12):3171-81, 2010.
PMID: 20423983; PMCID: PMC2930838.
60.
Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB,
Liu J. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished
apoptosis, and enhanced angiogenesis. Clin Cancer Res 16(15):3875-86, 2010. PMID: 20505188;
PMCID: PMC2930833.
61.
Yang H, Lu X, Qian J, Xu F, Hu Y, Yu Y, Bast RC, Li J. Imprinted tumor suppressor gene ARHI
induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. Mol
Med Rep 3(4):581-7, 2010. PMID: 21472283; PMCID: PMC3097896.
62.
Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, Du Y, Andreeff M, Hortobagyi GN, Hung
MC. Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signalregulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res 70(11):4709-18,
2010. PMID: 20484037; PMCID: PMC2895805.
63.
Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E,
Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE. Development of a multimarker assay
for early detection of ovarian cancer. J Clin Oncol 28(13):2159-66, 2010. PMID: 20368574; PMCID:
PMC2860434.
64.
Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Naora H, Auersperg N, Mills
GB, Bast RC, Liu J. Induction of papillary carcinoma in human ovarian surface epithelial cells
using combined genetic elements and peritoneal microenvironment. Cell Cycle 9(1):140-6, 2010.
PMID: 20016289; PMCID: PMC2931318.